Modeling and Simulation - PK/PD Archives | 第 21 页，共 37 页

Publication

Cardiac Safety Research Consortium: Can the Thorough QT/QTc Study Be Replaced by Early QT Assessment in Routine Clinical Pharmacology Studies? Scientific Update and a Research Proposal for a Path Forward

The International Conference on Harmonization E14 guidance for the clinical evaluation of QT/QTc interval prolongation…

Danielle Pillsbury2014 年 9 月 1 日

Publication

Understanding the Effect of the HCV Polymerase Inhibitor Mericitabine on Early Viral Kinetics in the Phase 2 JUMP-C and PROPEL Studies

Danielle Pillsbury2014 年 8 月 21 日

Knowledge Base

Adding a Placebo Component to Your PK/PD Model in Phoenix

PK/PD modeling is an exciting are of research in clinical pharmacology. Most often we try…

Nathan Teuscher2014 年 8 月 20 日

Knowledge Base

Bioanalytical Calibration Curves

At the request of a reader, I have decided to extend my series on bioanalysis…

Nathan Teuscher2014 年 8 月 12 日

Publication

Assessment of Tumor Growth Inhibition Metrics to Predict Overall Survival

Modeling and simulation is proposed to support drug development phase transitions in oncology. Longitudinal tumor-size…

Danielle Pillsbury2014 年 8 月 1 日

Knowledge Base

Radiometric Analysis

One of the oldest methods used for the quantitation of drug molecules is radiometric analysis.…

Nathan Teuscher2014 年 7 月 29 日

Blog Knowledge Base

Understanding LC/MS/MS

The most common bioanalytical method in use today is LC/MS/MS, or liquid chromatography (LC) tandem…

Certara2014 年 7 月 15 日

Publication

Population Pharmacokinetic Analysis of Dutogliptin, a Selective Dipeptidyl Peptidase-4 Inhibitor

Dutogliptin is a selective dipeptidyl peptidase-4 inhibitor shown to be efficacious and safe in patients…

Danielle Pillsbury2014 年 7 月 14 日

Publication

Application of a Physiologically-based Pharmacokinetic Model to Predict OATP1B1-related Variability in Pharmacodynamics of Rosuvastatin

Typically, pharmacokinetic-pharmacodynamic (PK/PD) models use plasma concentration as the input that drives the PD model. However, interindividual variability in…

Danielle Pillsbury2014 年 7 月 9 日

知识库

What is HPLC/UV?

In my series about bioanalysis for the pharmacokineticist, I thought I would start with the…

Nathan Teuscher2014 年 7 月 8 日

Modeling and Simulation – PK/PD

Cardiac Safety Research Consortium: Can the Thorough QT/QTc Study Be Replaced by Early QT Assessment in Routine Clinical Pharmacology Studies? Scientific Update and a Research Proposal for a Path Forward

Understanding the Effect of the HCV Polymerase Inhibitor Mericitabine on Early Viral Kinetics in the Phase 2 JUMP-C and PROPEL Studies

Adding a Placebo Component to Your PK/PD Model in Phoenix

Bioanalytical Calibration Curves

Assessment of Tumor Growth Inhibition Metrics to Predict Overall Survival

Radiometric Analysis

Understanding LC/MS/MS

Population Pharmacokinetic Analysis of Dutogliptin, a Selective Dipeptidyl Peptidase-4 Inhibitor

Application of a Physiologically-based Pharmacokinetic Model to Predict OATP1B1-related Variability in Pharmacodynamics of Rosuvastatin

What is HPLC/UV?

订阅时事通讯

快捷链接

解决方案

联系我们